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Abstract 
In patients with arterial hypertension (AH) pharmacotherapy often remains ineffective 
because of comorbid pathology. Research of haemodynamic and homeostatic processes in 
such patients allows prescribe effective antihypertensive medicines, improve life quality and 
prognosis.  Material and methods: 60 patients with AH, coronary artery disease and obesity 
were divided into three groups: 1st group was treated with  lisinopril + atorvastatin + aspirin 
(regimen I); 2nd group was treated with lisinopril + atorvastatin + bisoprolol + aspirin 
(regimen II); 3rd group was treated with lisinopril + bisoprolol + indapamide + atorvastatin + 
aspirin (regimen III). Laser correlation spectrometry (LCS) was used to evaluate the 
homeostatic alterations. Results: All regimens were equally effective in normalization of 
systolic blood pressure and did not influence the ejection fraction. Only in the 3rd group was 
determined significant increase of glomerular filtration rate (92.732.12 vs 79.6213.62 
ml/min/1.73m2). The LCS test showed that these patients had high level of light scattering 
particles IV, which may be caused by activation of anabolic processes. In other groups, 
spectral alterations were not so expressive. Conclusions: Prescription of antihypertensive 
therapy cause homeostatic and metabolic alterations, which may influence the efficacy of 
treatment. 
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INTRODUCTION 
A considerable growth of cardio-vascular diseases, especially among the elder 
patients, is observed all over the world and in Ukraine. Primary hypertension (PH) and 
coronary artery disease (CAD) are the main causes of cardio-vascular morbidity (41.8% / 
38.3, accordingly) [1]. PH combined with CAD make worse patient's prognosis and lead to 
adverse outcomes [2]. High level of systolic blood pressure is one of the main risk factors of 
CAD and its complications [3]. Thus, addition of CAD to PH increases cardiovascular risk to 
high level [4]. It was proved by PROGRESS investigation, which confirmed that every 4th 
death from CAD is caused by increased blood pressure [3]. In elderly patients, PH is 
complicated with CAD in 67.7% cases [1].  
In patients with CAD combined with PH obesity is one of the most common 
comorbidities [5]. Our previous investigations determined negative impact of the obesity in 
heart failure, atrial fibrillation and decompensation of the patient state [6]. Patients with 
obesity and PH have high cardiac preload caused by the growth of circulating blood volume 
and high postload caused by high arterial stiffness [7].  
In the elderly patients, choice of effective pharmacotherapy (PT) is complicated with 
numerous comorbidities, pharmacokinetic and pharmacodynamic peculiarities [8, 9, 10]. 
Nowadays there are not enough methods, which allow to determine the influence of PT on 
metabolic processes [8, 11]. This leads to low efficacy of antihypertensive treatment [3]. So it 
is important to provide complex sanogenetic monitoring in all patients with PH. Laser 
correlation spectrometry (LCS) is one of the most common methods, which allows quickly 
determine and analyze the metabolic disorders [12, 13, 14].  
MATERIAL AND METHODS 
In Odessa University Clinic (Ukraine) 60 patients with PH, CAD and obesity were 
treated according to clinical recommendations [4, 15, 17, 18]. All patients were divided into 
three groups: the 1st (n=20) was given lisinopril + atorvastatin + aspirin (regimen I), the 2nd 
(n=20) was given lisinopril + atorvastatin + bisoprolol + aspirin (regimen II); the 3rd (n=20) 
was given lisinopril + bisoprolol + indapamide + atorvastatin + aspirin (regimen III). 
Exclusion criteria: myocardial infarction and stroke in anamnesis. Body mass index (BMI) 
and glomerulal filtration rate (GFR) were calculated in all patients.  
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The special research method for estimation of plasma metabolic features was LCS 
[13]. It helps to measure spectral characteristics of the induced monochromatic coherent 
radiation in biological liquids. That makes possible to register particles with hydrodynamic 
radius 1 - 10000 nanometers. Results are presented as a histogram. 
According to our previous studies [13], to the I zone (0-10 nanometers) are included 
low-molecular monomeric albumins and glycolipid free complexes; to the II zone (11-30 
nanometers) are included globulin proteins and low-molecular lipoprotein complexes; to the 
III zone (31-70 nanometers) are included high-molecular lipoprotein complexes, RNP-,  DNP 
molecules, the low-molecular immune complexes; to the IV zone (71-150 nanometers) are 
included mainly constitutive immune complexes of the average size. Huge particles (≥ 150 
nanometers, the V zone) are present in patients with allergization and an autoimmune 
sensibilization. The particle distribution and their molecular interaction characterizes different 
pathological states. The presence of xenobiotics (e.g. medicines) causes specific changes of 
the initial distribution and may characterize the treatment efficacy. Metabolic features were 
determined in blood plasma before and on the 10th day of PT. The investigation was carried 
out according to the method after Bazhora J.I. and Noskin L.A. [14].  
The statistical analyze was provided with Statistica 7.0. To measure differences 
between values before and after the treatment we used t-test; p-value of < 0.05 was considered 
to be statistically significant. Values are presented as Mean ± Standard deviation (SD). 
RESULTS 
Mean age (MA) of the investigated patients was 67.2±5.1 years. Among them were 28 
males (MA 66.2±8.9 years) and 32 females (MA 68.3±7.4 years). All of them had obesity 
with BMI corresponding to the first stage (BMI: 30-35 kg / m2). Diabetes mellitus was 
diagnosed in 26.31% patients in the 1st group, in 15% in the 2nd group and in 25% in the 3rd 
group.  
Before and after the prescription of antihypertensive therapy we determined changes 
of heart rate (HR), systolic and diastolic blood pressure (SBP, DBP), ejection fraction (EF), 
total cholesterol and levels (tab. 1).  
After the treatment in the 1st group was determined the decrease of SBP (by 35.0 mm 
Hg), DBP (by 12.4 mm Hg) and HR (by 14/min). EF, GFR and glucose levels remained 
without any changes. Total cholesterol decreased by 1.68 mcmol/L.  
In the 2nd group SBP decreased by 20.91 mm Hg. DBP, HR and EF remained the 
same. Cholesterol reached the normal values (4.78 mmol/L) but glucose level increased by 
1.14 mmol/L (p>0.05).  
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In the 3rd group SBP decreased by 29.8 mm Hg, DBP by 14 mm Hg, HR by 9.73/min. 
Cholesterol level reached the target borders (4.68 mmol/l). EF and glucose level remained the 
same. GFR rate increased to 92.73 ml/min/1.73m2. 
Table 1 
Clinical data of all the investigated groups before and after PT 
Clinical 
data 
Regimen I Regimen II Regimen III 
Before the 
treatment 
During the 
treatment 
Before the 
treatment 
During the 
treatment 
Before the 
treatment 
During the 
treatment 
SBP, mm 
Hg 
163.216.1 128.08.6* 151.36.2 130.46.0* 160.711.5 130.99.1 * 
DBP, mm 
Hg 
87.38.5 75.04.6* 83.06.6 85.06.3 94.07.1 80.06.6 * 
HR, bpm 79.613.1 65.69.0* 72.35.1 68.211.2 81.114.7 71.713.0 * 
EF, % 64.86.6 65.66.3 59.88.2 60.68.1 59.39.3 58.88.7 
Cholester
ol, 
mcmol/L 
6.31.8 4.60.4* 6.41.2 4.80.4* 5.90.9 4.60.6* 
Glucose, 
mmol/L 
6.01.7 6.31.3 5.40.7 6.51.4 6.51.9 6.70.8 
GFR, 
ml/min/1.
73m2 
81.713.7 78.412.6 79.414.8 76.612.1 79.613.6 92.712.1 * 
*, p< 0.05 vs before treatment. 
 
LCS data showed that only regimen III caused a significant growth of light scattering 
particles (LSP) IV (on 11.1%), which characterize anabolic reactions. Before the prescription 
of regimens I and II prevalence of LSP II, III and IV was observed.  It is typical for catabolic, 
toxic and allergy-directed reactions.  
These alterations remained without any significant changes after the treatment (tabl. 
2). 
Table 2 
Subfractional redistribution before and after PT 
LSP 
redistribution 
Regimen I Regimen II Regimen III 
Before PT, 
% 
During 
PT, % 
Before PT, 
% 
During 
PT, % 
Before PT, 
% 
During 
PT, % 
I zone  8.5 7.3 9.4 9.4 10.3 9.2 
II zone 27.4 22.9 37.4 29.2 29.7 26.7 
III zone 27.6 32.5 21.4 25.2 27.0 20.6 
IV zone 33.3 30.9 22.6 26.2 19.3 30.4* 
V zone 3.2 6.4 9.2 10.0 13.7 13.1 
*, p< 0.05 vs before treatment.  
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Concerning spectral alterations, we determined that hydrolytic alterations remained the 
same after the prescription of regimen I. Normological type even decreased by 15.0% and 
anabolic type increased the same value due to autoimmune reactions. Regimen II caused the 
decrease of hydrolytic reactions by 25.0% and growth of anabolic reactions by 15.0%.  
Regimen III was characterised by increase of hydrolytic and anabolic type reactions (10.0% / 
25.0%, accordingly) (tabl. 3).   
Table 3 
Direction of spectral alterations before and after PT 
Type of 
spectral 
alteration 
Regimen I Regimen II Regimen III 
Before 
PT, % 
During 
PT, % 
Before 
PT, % 
During 
PT, % 
Before 
PT, % 
During PT, 
% 
Normological 25.0 10.0* 0 5.0 15.0 10.0 
Hydrolytic 40.0 40.0 65.0 55.0* 35.0 45.0* 
Anabolic 15.0 30.0* 15.0 30.0* 5.0 30.0* 
Mixed 20.0 20.0 20.0 10.0* 45.0 15.0* 
*, p< 0.05 vs before treatment. 
 
DISCUSSION 
As we observed from abovementioned data, all the three regimens equally caused 
stabilization of SBP, which is the main target of antihypertensive PT [19]. DBP was 
significantly lowered with the Ist and IIIrd regimens, but in the IInd regimen it remained 
without changes. Significant lowering of HR was achieved after the prescription of lisinopril. 
We did not determine any influence of used PT on EF rate. 
In all three groups, total cholesterol level was brought to the normal values.  Regimen 
II increased glucosa level, but not statistically significant. GFR rate didn’t changed after 
regimens I and II, but regimen III caused growth of GFR. Thus, as we see, such a step-by-step 
prescription of each new drug is very convenient for observing of it’s influence and helps us 
to optimise the treatment.  
LCS data showed that regimens I and II didn’t change the subfractional structure and 
only regimen III caused the growth of anabolic reactions. To estimate PT influence on 
metabolic processes we have to take into account not only subfractional structure but also 
directions of spectral alterations.   
We also have to take into account initial alterations and compare them with alterations 
after the PT. Otherwise, the received data could be incorrectly interpreted.  
So, regimen I caused lowering of normological type and in spite of anabolic reactions 
growth, hydrolytic type remained the same as before the treatment. Thus, regimen I is not 
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effective in correction of hydrolytic reactions. Addition of bisoprolol (regimen II) caused 
decrease of hydrolytic reactions and simultaneous increase of anabolic ones. So, regimen II 
change hydrolytic as anabolic processes. Regimen III (which included indopamide) caused 
increase of hydrolytic and anabolic reactions. So, as we see, we have to compare both LCS 
data: LSP redistribution and spectral alterations in order to estimate PT influence on 
metabolic processes. In our investigation spectral alterations appeared to be more informative 
because of proved statistical significance. 
CONCLUSIONS. 
All the prescribed regimens are optimal for SPB stabilization but they do not influence 
EF. In elderly patients with PH and comorbid pathologies PT should be individualized. LCS 
is very sensitive method, which allows determine homeostatic alterations and metabolic 
transformations in the process of treatment. Addition of LCS to basic clinical, laboratory, and 
instrumental data helps to choose an appropriate PT. 
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